Funciones de peso Forma de las part´ıculas

Investigating the use of texture analysis in patients receiving SABR is appropriate because: it has the potential to be cost effective; it can be completed on existing imaging; can potentially be used to help define malignancy or recurrence when a patient cannot have a biopsy; and the use of SABR is likely to increase.

The next chapter (chapter 3) focuses on different methods of TA to establish the context of TA in lung cancer. Chapters 4-6 establish and investigate a specific method of TA in patients who have received SABR for NSCLC.

50 References

ALLEMANI, C., WEIR, H. K., CARREIRA, H., HAREWOOD, R., SPIKA, D., WANG, X. S., BANNON, F., AHN, J. V., JOHNSON, C. J., BONAVENTURE, A., MARCOS-GRAGERA, R., STILLER, C., AZEVEDO E SILVA, G., CHEN, W. Q., OGUNBIYI, O. J., RACHET, B., SOEBERG, M. J., YOU, H., MATSUDA, T., BIELSKA-LASOTA, M., STORM, H., TUCKER, T. C., COLEMAN, M. P. & GROUP, C. W. 2015. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 385, 977-1010.

BALL, D., MAI, T., VINOD, S., BABINGTON, S., RUBEN, J., KRON, T., CHESSON, B., HERSCHTAL, A., REZO, A., ELDER, C., SKALA, M., WIRTH, A., WHEELER, G., LIM, A., VANEVSKI, M. & SHAW, M. 2017. A Randomized Trial of SABR vs Conventional Radiotherapy for Inoperable Stage I Non- Small Cell Lung Cancer: TROG09.02 (CHISEL). Journal of Thoracic Oncology, 12, S1853. CHANG, J. Y., LI, Q. Q., XU, Q. Y., ALLEN, P. K., REBUENO, N., GOMEZ, D. R., BALTER, P., KOMAKI, R.,

MEHRAN, R., SWISHER, S. G. & ROTH, J. A. 2014. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys, 88, 1120-8.

CHANG, J. Y., SENAN, S., PAUL, M. A., MEHRAN, R. J., LOUIE, A. V., BALTER, P., GROEN, H. J., MCRAE, S. E., WIDDER, J., FENG, L., VAN DEN BORNE, B. E., MUNSELL, M. F., HURKMANS, C., BERRY, D. A., VAN WERKHOVEN, E., KRESL, J. J., DINGEMANS, A. M., DAWOOD, O., HAASBEEK, C. J., CARPENTER, L. S., DE JAEGER, K., KOMAKI, R., SLOTMAN, B. J., SMIT, E. F. & ROTH, J. A. 2015. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 16, 630-7.

COLEMAN, M. P., FORMAN, D., BRYANT, H., BUTLER, J., RACHET, B., MARINGE, C., NUR, U., TRACEY, E., COORY, M., HATCHER, J., MCGAHAN, C. E., TURNER, D., MARRETT, L., GJERSTORFF, M. L., JOHANNESEN, T. B., ADOLFSSON, J., LAMBE, M., LAWRENCE, G., MEECHAN, D., MORRIS, E. J., MIDDLETON, R., STEWARD, J., RICHARDS, M. A. & GROUP, I. M. W. 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet, 377, 127-38.

GINSBERG, R. J. & RUBINSTEIN, L. V. 1995. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg, 60, 615-22; discussion 622-3.

LAGERWAARD, F. J., AARONSON, N. K., GUNDY, C. M., HAASBEEK, C. J., SLOTMAN, B. J. & SENAN, S. 2012. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol, 7, 1148-54.

LOUIE, A. V., PALMA, D. A., DAHELE, M., RODRIGUES, G. B. & SENAN, S. 2015. Management of early- stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol, 114, 138-47.

MAHMOOD, S., BILAL, H., FAIVRE-FINN, C. & SHAH, R. 2013. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg, 17, 845-53.

MORRIS, E. J., FINAN, P. J., SPENCER, K., GEH, I., CRELLIN, A., QUIRKE, P., THOMAS, J. D., LAWTON, S., ADAMS, R. & SEBAG-MONTEFIORE, D. 2016. Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service. Clin Oncol (R Coll Radiol), 28, 522-31.

MURRAY, L., RAMASAMY, S., LILLEY, J., SNEE, M., CLARKE, K., MUSUNURU, H. B., NEEDHAM, A., TURNER, R., SANGHA, V., FLATLEY, M. & FRANKS, K. 2016a. Stereotactic Ablative

51

Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort. Clin Oncol (R Coll Radiol), 28, 4-12. MURRAY, P., FRANKS, K. & HANNA, G. G. 2016b. A systematic review of outcomes following

Stereotactic Ablative Radiotherapy in the treatment of early stage primary lung cancer. The British journal of radiology, 20160732.

NANDA, R. H., LIU, Y., GILLESPIE, T. W., MIKELL, J. L., RAMALINGAM, S. S., FERNANDEZ, F. G., CURRAN, W. J., LIPSCOMB, J. & HIGGINS, K. A. 2015. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer, 121, 4222-30.

NYMAN, J., HALLQVIST, A., LUND, J., BRUSTUGUN, O. T., BERGMAN, B., BERGSTRÖM, P., FRIESLAND, S., LEWENSOHN, R., HOLMBERG, E. & LAX, I. 2016. SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol, 121, 1-8.

PALMA, D., LAGERWAARD, F., RODRIGUES, G., HAASBEEK, C. & SENAN, S. 2012. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys, 82, 1149-56.

PALMA, D., VISSER, O., LAGERWAARD, F. J., BELDERBOS, J., SLOTMAN, B. & SENAN, S. 2011.

Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol, 101, 240-4.

PALMA, D., VISSER, O., LAGERWAARD, F. J., BELDERBOS, J., SLOTMAN, B. J. & SENAN, S. 2010. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol, 28, 5153-9.

PHILLIPS, I., HENSON, K., LAWTON, S., BROCK, R. & EZHIL, V. 2018. Assessing the use of SABR in stage 1 non-small cell lung cancer in England: the use of the National Radiotherapy Data Set. Lung Cancer, 30, e56.

PIGNON, J. P., TRIBODET, H., SCAGLIOTTI, G. V., DOUILLARD, J. Y., SHEPHERD, F. A., STEPHENS, R. J., DUNANT, A., TORRI, V., ROSELL, R., SEYMOUR, L., SPIRO, S. G., ROLLAND, E., FOSSATI, R., AUBERT, D., DING, K., WALLER, D., LE CHEVALIER, T. & GROUP, L. C. 2008. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.

SAUNDERS, M., DISCHE, S., BARRETT, A., HARVEY, A., GRIFFITHS, G. & PALMAR, M. 1999. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol, 52, 137-48.

SENTHI, S., HAASBEEK, C. J., SLOTMAN, B. J. & SENAN, S. 2013. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol, 106, 276-82. SENTHI, S., LAGERWAARD, F. J., HAASBEEK, C. J., SLOTMAN, B. J. & SENAN, S. 2012. Patterns of

disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol, 13, 802-9.

SONG, M. A., BENOWITZ, N. L., BERMAN, M., BRASKY, T. M., CUMMINGS, K. M., HATSUKAMI, D. K., MARIAN, C., O'CONNOR, R., REES, V. W., WOROSZYLO, C. & SHIELDS, P. G. 2017. Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst, 109.

TASKFORCE, I. C. 2015. Achieving world class cancer outcomes 2015-2020. Cancer Research UK. UK, C. R. 2015. Lung cancer [Online]. CRUK website. Available:

http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer- tpe/lung-cancer#heading-Zero. [Accessed May 2015].

VANSTEENKISTE, J., CRINÒ, L., DOOMS, C., DOUILLARD, J. Y., FAIVRE-FINN, C., LIM, E., ROCCO, G., SENAN, S., VAN SCHIL, P., VERONESI, G., STAHEL, R., PETERS, S., FELIP, E. & MEMBERS, P. 2014. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol, 25, 1462-74.

52

WALTERS, S., MARINGE, C., COLEMAN, M. P., PEAKE, M. D., BUTLER, J., YOUNG, N., BERGSTRÖM, S., HANNA, L., JAKOBSEN, E., KÖLBECK, K., SUNDSTRØM, S., ENGHOLM, G., GAVIN, A.,

GJERSTORFF, M. L., HATCHER, J., JOHANNESEN, T. B., LINKLATER, K. M., MCGAHAN, C. E., STEWARD, J., TRACEY, E., TURNER, D., RICHARDS, M. A., RACHET, B. & GROUP, I. M. W. 2013. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax, 68, 551-64.

WANG, C. Y., LIN, Y. S., TZAO, C., LEE, H. C., HUANG, M. H., HSU, W. H. & HSU, H. S. 2007.

Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg, 32, 877-81.

WIENER, R. S., SCHWARTZ, L. M., WOLOSHIN, S. & WELCH, H. G. 2011. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med, 155, 137-44.

53

Theme 1: CT Texture Analysis after SABR for Non-Small Cell Lung Cancer

Chapter 3: Literature review of Clinical Applications of texture analysis in Non-Small Cell